Payment overview · 2025
General Payments
$16,097.70
204 reported records · 16 companies
Healthcare provider profile · identity verified
Jaskanwal Singh Bisla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · CHANDLER, AZ · NPI 1003127457
Verified facts
What the public records show
CMS Open Payments records show Jaskanwal Singh Bisla, M.D. received $16,097.70 in general payments during 2025 across 204 reported records.
Boston Scientific Corporation accounted for 50.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $8,142.65 | 50.6% | 63 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,958.69 | 18.4% | 43 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $2,437.60 | 15.1% | 54 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$971.08 | 6.0% | 13 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $808.30 | 5.0% | 11 | 2025 |
| Elutia, Inc. | Unresolved — no canonical attribution shown | $175.00 | 1.1% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $122.04 | 0.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $113.69 | 0.7% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $110.00 | 0.7% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $92.10 | 0.6% | 8 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $53.33 | 0.3% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $30.35 | 0.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $24.35 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.40 | 0.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20.37 | 0.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.75 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $10,020.81 | 189 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,750.00 | 3 |
| Travel and Lodging | $2,326.89 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $3,750.00 | 3 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $2,026.39 | 24 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,670.42 | 11 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $1,536.42 | 36 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $1,441.70 | 9 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $923.01 | 33 | 2025 |
Source payment records
|
|||||
| QDOT MICRO Normalized: qdot micro |
Device | Biosense Webster, Inc. | $826.58 | 16 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $589.38 | 6 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $439.58 | 4 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $282.02 | 5 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $209.06 | 6 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $184.89 | 2 | 2025 |
Source payment records
|
|||||
| ECM Patch,Pouch Normalized: ecm patch pouch |
Device | Elutia, Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $152.37 | 4 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $122.04 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $115.37 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $113.69 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $110.00 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $92.10 | 8 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $73.55 | 6 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $68.14 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $61.55 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $60.31 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $53.33 | 2 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $40.55 | 1 | 2025 |
Source payment records
|
|||||
| OCTARAY MAPPING CATHETER Normalized: octaray mapping catheter |
Device | Biosense Webster, Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| Electrophysiology Cable Normalized: electrophysiology cable |
Device | Boston Scientific Corporation | $7.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Xarelto | Rivaroxaban | 86 | 25 |
| Eliquis | Apixaban | 82 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 35 |
| Flecainide Acetate | Flecainide Acetate | 49 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 29 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,097.70 · 204 records | Boston Scientific Corporation | AFFERA MAPPING SYSTEM, AURORA EV-ICD MRI SURESCAN, AVEIR, Assure WCD, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, COBALT DR MRI SURESCAN, ECM Patch,Pouch, ENSITE, ENSITE PRECISION, Electrophysiology Cable, FARAPULSE, FLOWTRIEVER, GALLANT, General - EP, General - Therapies, Hillrom - Carnation Ambulatory Monitor, INSPIRE, JARDIANCE, LM Undivided, LifeVest, MICRA, NUVISION ICE CATHETER, OCTARAY MAPPING CATHETER, PERCLOSE PROSTYLE, PULSESELECT, QDOT MICRO, RESONATE EL ICD VR, Rhythmia Mapping System, SELECTSECURE, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error